

	Document ID	Title
1	US 6217869 B1	Pretargeting methods and compounds
2	US 6190640 B1	Method for treating neoplasia using humanized antibodies which bind to antigen A33
3	US 6132697 A	Radiopharmaceutical compositions capable of localizing at sites of thrombus
4	US 6096874 A	High affinity tamoxifen derivatives
5	US 5985826 A	Methods of using hepatic-directed compounds in pretargeting strategies
6	US 6277375 B1	Immunoglobulin-like domains with increased half-lives
7	US 6180082 B1	Method to enhance tissue accumulation of radiolabeled compounds

	Document ID	Title
8	US 5985240 A	Peptide radiopharmaceutical applications
9	US 6177410 B1	Therapeutic methods for prostate cancer
10	US 5843439 A	<p>Therapeutic application of chimeric and radiolabeled antibodies to human</p> <p>B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma</p>

It will be appreciated that the actual preferred amount of the compound to be administered according to the present invention will vary according to the particular compound, the particular composition formulated, and the mode of administration. Many factors that may modify the action of the inhibitor can be taken into account by those skilled in the art; e.g., body weight, diet, time of administration, route of administration, rate of excretion, condition of the subject, drug combinations, and reaction sensitivities and severities. Administration can be carried out continuously or periodically within the maximum tolerated dose. Optimal administration rates for a given set of conditions can be ascertained by those skilled in the art using conventional dosage administration tests. US 6019957

Choice of molecular species of antibody for therapy applications of radionuclides is more complex. In addition to physical and biologic half-lives, residence time of the labeled antibody in the tumor, energy of the emission and contribution of total body to specific organ dose are critical issues that dictate the optimal size of antibody or fragment. With monoclonal antibodies, the particular antibody will also be a factor influencing the choice. US 5,556,982

L Number	Hits	Search Text	DB	Time stamp
1	149303	dose or dosage or dosimetry	USPAT; US-PGPUB	2001/08/30 11:46
4	16817	radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2))	USPAT; US-PGPUB	2001/08/30 12:24
7	10120	(dose or dosage or dosimetry) and (radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2)))	USPAT; US-PGPUB	2001/08/30 11:48
10	36	((dose or dosage or dosimetry) and (radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2)))) and (clearance adj profile)	USPAT; US-PGPUB	2001/08/30 11:57
13	9810	((dose or dosage or dosimetry) and (radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2)))) and (calculat\$2 or determin\$3 or equation)	USPAT; US-PGPUB	2001/08/30 11:58
16	6108	((dose or dosage or dosimetry) and (radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2)))) and (calculat\$2 or equation)	USPAT; US-PGPUB	2001/08/30 12:00
19	5473	((dose or dosage or dosimetry) and (radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2)))) and (calculat\$2 or determin\$3 or equation)) and (424/\$.ccls. or 514/\$.ccls.)	USPAT; US-PGPUB	2001/08/30 12:01
22	139	((dose or dosage or dosimetry) and (radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2)))) and (calculat\$2 or determin\$3 or equation)) and (424/\$.ccls. or 514/\$.ccls.)) and mass and clearance and activity and (residence or resident) and (effective or therapeutic)	USPAT; US-PGPUB	2001/08/30 12:24
25	16819	radiopharmacology or radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2))	USPAT; US-PGPUB	2001/08/30 12:26
28	912	tolerated adj dose	USPAT; US-PGPUB	2001/08/30 12:27
31	12838	effective adj dose	USPAT; US-PGPUB	2001/08/30 12:27
34	3309	therapeutic adj dose	USPAT; US-PGPUB	2001/08/30 12:27
37	19	total adj body adj dose	USPAT; US-PGPUB	2001/08/30 12:28
40	2174	total adj body	USPAT; US-PGPUB	2001/08/30 12:29
43	2119	body adj mass	USPAT; US-PGPUB	2001/08/30 12:29
46	2272	effective adj mass	USPAT; US-PGPUB	2001/08/30 12:29
49	39875	residence adj time	USPAT; US-PGPUB	2001/08/30 12:30
52	1502	activity adj (hours or time)	USPAT; US-PGPUB	2001/08/30 12:31
55	0	(radiopharmacology or radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2))) and (tolerated adj dose) and (effective adj dose) and (therapeutic adj dose) and (total adj body adj dose) and (total adj body) and (body adj mass) and (effective adj mass) and (residence adj time) and (activity adj (hours or time))	USPAT; US-PGPUB	2001/08/30 12:34
58	0	(tolerated adj dose) and (effective adj dose) and (therapeutic adj dose) and (total adj body adj dose) and (total adj body) and (body adj mass) and (effective adj mass) and (residence adj time) and (activity adj (hours or time))	USPAT; US-PGPUB	2001/08/30 12:34
61	126	(radiopharmacology or radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2))) and (tolerated adj dose)	USPAT; US-PGPUB	2001/08/30 13:45
64	1688	(radiopharmacology or radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2))) and (effective adj dose)	USPAT; US-PGPUB	2001/08/30 13:45
67	27	(radiopharmacology or radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2))) and (effective adj dose) and (residence adj time)	USPAT; US-PGPUB	2001/08/30 13:51

70	15	(radiopharmacology or radiopharmaceutical or radiolabel\$2 or iodinat\$2 or (radio adj (pharmaceutical or label\$2))) and (effective adj dose) and (activity adj (hours or time))	USPAT; US-PGPUB	2001/08/30 13:52
73	0	(therapeutic adj dose) and (total adj body) and (body adj mass) and (effective adj mass)	USPAT; US-PGPUB	2001/08/30 13:52